These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 15808387)
1. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Salvatore S; Khullar V; Cardozo L; Milani R; Athanasiou S; Kelleher C Eur J Obstet Gynecol Reprod Biol; 2005 Apr; 119(2):237-41. PubMed ID: 15808387 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Kennelly MJ; Lemack GE; Foote JE; Trop CS Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264 [TBL] [Abstract][Full Text] [Related]
3. [Therapeutic effects of intrarectal administration of oxybutynin]. Radziszewski P; Borkowski A Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351 [TBL] [Abstract][Full Text] [Related]
4. [Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women]. Serrano Brambila EA; Quiroga Avila RG; Lorenzo Monterrubio JL; Moreno Aranda J Ginecol Obstet Mex; 2000 Apr; 68():174-81. PubMed ID: 10824450 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW; J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314 [TBL] [Abstract][Full Text] [Related]
6. A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability. Soomro NA; Khadra MH; Robson W; Neal DE J Urol; 2001 Jul; 166(1):146-9. PubMed ID: 11435843 [TBL] [Abstract][Full Text] [Related]
7. [Topical administration of oxybutynin hydrochloride in women with urge incontinence. Results of a prospective randomized double-blind study]. Enzelsberger H; Kurz C; Helmer H; Mittermayer F Geburtshilfe Frauenheilkd; 1995 May; 55(5):240-3. PubMed ID: 7607378 [TBL] [Abstract][Full Text] [Related]
8. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. Corcos J; Casey R; Patrick A; Andreou C; Miceli PC; Reiz JL; Harsanyi Z; Darke AC; BJU Int; 2006 Mar; 97(3):520-7. PubMed ID: 16469019 [TBL] [Abstract][Full Text] [Related]
10. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence. Radomski SB; Caley B; Reiz JL; Miceli PC; Harsanyi Z; Darke AC Curr Med Res Opin; 2004; 20(2):249-53. PubMed ID: 15006020 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131 [TBL] [Abstract][Full Text] [Related]
12. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ; Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176 [TBL] [Abstract][Full Text] [Related]
13. Detrusor overactivity in spina bifida: how long does it need to be treated? Ab E; Dik P; Klijn AJ; van Gool JD; de Jong TP Neurourol Urodyn; 2004; 23(7):685-8. PubMed ID: 15382196 [TBL] [Abstract][Full Text] [Related]
14. A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. Karademir K; Baykal K; Sen B; Senkul T; Iseri C; Erden D Scand J Urol Nephrol; 2005; 39(3):230-3. PubMed ID: 16118096 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Abrams P; Cardozo L; Chapple C; Serdarevic D; Hargreaves K; Khullar V; Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644 [TBL] [Abstract][Full Text] [Related]
16. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. Rajkumar GN; Small DR; Mustafa AW; Conn G BJU Int; 2005 Oct; 96(6):848-52. PubMed ID: 16153215 [TBL] [Abstract][Full Text] [Related]
17. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380 [TBL] [Abstract][Full Text] [Related]
18. Treatment with modified intravesical oxybutynin chloride for neurogenic bladder in children. Hayashi A; Saito M; Okada S; Hanada T; Watanabe T; Satoh K; Kanzaki S J Pediatr Urol; 2007 Dec; 3(6):438-42. PubMed ID: 18947791 [TBL] [Abstract][Full Text] [Related]
19. Transdermal oxybutynin: sticking to the facts. Cartwright R; Cardozo L Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979 [TBL] [Abstract][Full Text] [Related]